spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman


Professor Howell has over 20 years’ life science commercialisation experience, supporting companies’ development and profitability. He founded Innova Partnerships in 2006, where he has been instrumental in creating over a dozen life science start-ups and raised in excess of £100m in financing. Steve oversaw the exit of Innova Biosciences in 2016-2017 to SYGNIS AG, Innova Partnerships’ second exit. He has held positions at Unilever plc, and was previously Director of Business Development at Alere Inc. and Research Director at Unipath Ltd. In 2015 he was made Visiting Professor of Commercial Innovation at King's College, London.

Professor Steve Howell, Non-Executive Chairman, Arcis Biotechnology, commented:“The Arcis sample preparation technology has enormous potential across many application areas, including diagnostics and genetic understanding. I am excited to be joining the team as we build the business to bring products to market that will have real and positive impact on patient quality of life.”

Paul Foulger, Non-Executive Director, Arcis Biotechnology, said:"We have an exciting opportunity to build a world-leading and highly valuable biotech based on Arcis’ current technology platform and future ambitions. Steve’s considerable experience, expertise and network will make a significant contribution to achieving that goal and delivering maximum value to shareholders.”

Peter Whitehurst, CEO, Arcis Biotechnology, said: “I would like to thank Paul for his time as interim Chairman, and for working with the Executive Directors to bring Steve in for the next exciting phase of development at Arcis.”

The appointment of Professor Howell as Non-Executive Chairman follows the Company’s recent announcements of strategic distribution and licensing agreements, with Opentrons and Mirnax Biosens respectively. These agreements extend the reach of Arcis’ sample preparation and preservation technology in two areas of the life sciences industry – high throughput sample prep with robotics, and the development of early disease diagnostics.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

TrialScope Taps Industry Veteran as CTO

JERSEY CITY, NJ, July 29, 2019 – TrialScope, the global leader in clinical trial transparency and compliance solutions, announces the appointment of Ruben Echandy as Chief Technology Officer.
More info >>


White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement